IOVAIovance Biotherapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+12969.7% YoY

Gross Profit

-$262,000-0.8% margin

Operating Income

-$102M-327.6% margin

Net Income

-$97M-312.2% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+4250.5%

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$99M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$964M

Total Liabilities

$196M

Stockholders' Equity

$769M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$238,000	+12969.7%
Gross Profit	-$262,000	-$2M	+85.5%
Operating Income	-$102M	-$110M	+7.4%
Net Income	-$97M	-$107M	+8.8%

Geographic Segments

UNITED STATES

$30M97%

Non-US

$1M3%

IOVA Q2 2024 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena